Sep 2026· Drug Discovery Today· Vol 31, pp.
104797
· 0 citations· 133 references
Medicine
TL;DR
This review classifies mutant IDH inhibitors by chemical scaffold and relates their binding in the allosteric pocket to structure-activity trends, isoform selectivity, brain penetration, and clinical outcome.
Abstract
Isocitrate dehydrogenase (IDH) enzymes convert isocitrate to α-ketoglutarate. When IDH1 or IDH2 is mutated, the enzyme gains a new function, and the oncometabolite D-2-hydroxyglutarate (D-2-HG) accumulates. Its epigenetic and metabolic effects depend on the tumor context. This review classifies mutant IDH inhibitors by chemical scaffold and relates their binding in the allosteric pocket to structure-activity trends, isoform selectivity, brain penetration, and clinical outcome. Mutant IDH1, mutant IDH2, pan-IDH, and covalent inhibitors are compared, with lessons from successful and failed clinical candidates. Resistance is treated separately: secondary mutations, isoform switching, metabolic adaptation, rational combinations, PROTAC degraders, and biomarkers. Since reduced 2-HG indicates target engagement rather than clinical benefit, design priorities for the next generation of IDH-directed agents are outlined.
A covalent fragment-based approach was used to develop IDH1-C269 selective inhibitors which prevent the key regulatory segment from forming an α-helix required for catalytic competency, and provide structurally validated inhibitors for further development.
Charles P. Brown, Elliot O. Harmer, Ariba Azam et al.· bioRxiv· 0 citations
I1Hit1 and I2Hit1 are highlighted as novel therapeutic compounds with efficient IDH-target inhibition to address epigenetic modification in GBM, and further experimental validation of these compounds is required to demonstrate potential inhibitors of IDH-driven metabolism in GBM.
Nivedhitha Tamilazhagan, S. Arumugam· Frontiers in Bioinformatics· 0 citations
Isocitrate dehydrogenase 1 (IDH1) is a cytosolic NADP+-dependent enzyme involved in cellular redox homeostasis and 2-oxoglutarate (2-OG) metabolism. Glioma-associated mutations in IDH1 confer a neomorphic enzymatic activity, resulting in the production and accumulation of the oncometabolite D-2-hydroxyglutarate (2-HG),...
W. Deuther-Conrad, T. Lai, Andreas Maurer et al.· EJNMMI Radiopharmacy and Che...· 0 citations
ALDH1B1 is a mitochondrial aldehyde dehydrogenase required for the survival of stem-like colorectal and pancreatic cancer cells. Isoform-specific guanidinyl antagonists of aldehyde dehydrogenases (IGUANAs) have been developed for ALDH1B1, and here we describe structure-activity relationship (SAR) studies of three scaff...
A. Tarhan, Zhi-Ping Feng, Daniel Fernández et al.· Journal of Medicinal Chemist...· 0 citations
Conventional cancer therapy has long been confronted by significant challenges, particularly drug resistance. Aldo-keto reductase family 1 member C3 (AKR1C3), an enzyme markedly overexpressed in diverse human malignancies and critically implicated in tumor progression and therapy resistance, has emerged as an attractiv...
Guo-Qi Yu, Qiao-Li Zhou, Nan Jiang et al.· Bioorganic chemistry (Print)· 0 citations
N6-Methyladenosine (m6A), the most abundant internal modification of eukaryotic mRNA, is dynamically reversed by the FeII/α-ketoglutarate-dependent dioxygenase ALKBH5, a key m6A “eraser” that regulates target mRNA fate through demethylation. ALKBH5 is aberrantly overexpressed in acute myeloid leukemia, glioblastoma, br...
Cheng-Cheng Deng, Hai Xu, Jian Pu et al.· Frontiers in Pharmacology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.